Stockreport

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Xencor, Inc.  (XNCR) 
Last xencor, inc. earnings: 2/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.xencor.com/investor-relations
PDF – Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 –– X [Read more]